Navigation Links
NIDA Avant-Garde-Medications Development Award winners announced
Date:9/20/2011

Scientists proposing to develop vaccines against methamphetamine and nicotine have been selected to receive NIDA's second Avant-Garde Awards for Innovative Medication Development Research. The two scientists, Dr. Thomas Kosten, of Baylor College of Medicine, Houston, and Dr. Peter Burkhard, of the University of Connecticut, Storrs, will each receive $500,000 per year for five years to support their research, according to the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

"Through this funding opportunity, NIDA once again strengthens its commitment toward developing safe and efficacious medications to treat addiction," said NIDA Director Nora D. Volkow, M.D. "This program expressly seeks to promote research projects that are ready for clinical translation and can accelerate the development of new medications."

Awardees are listed below:

Awardee: Thomas Kosten, Ph.D., Baylor College of Medicine
Project: Human methamphetamine vaccine

Dr. Kosten's group will accelerate the development of a methamphetamine vaccine, which is expected to undergo initial clinical trials within the next five years. At present there is no FDA-approved medication for methamphetamine addiction, so a vaccine could have substantial impact on the treatment of methamphetamine addiction.

Awardee: Peter Burkhard, Ph.D., University of Connecticut
Project: A peptide nanoparticle nicotine vaccine

Dr. Burkhard's lab plans to develop and test a novel type of vaccine that induces a strong immune response against nicotine without the need of chemical enhancers, which could result in a less expensive vaccine with fewer side effects. This nicotine vaccine will be administered intranasally, which will be more convenient and less painful than an injection. The new vaccine is expected to enter initial clinical trials within the next five years.

"Not only do these grantees have a strong background in vaccine research, but they also have clear plans for initiating clinical trials within an accelerated period of time," said Dr. Volkow. "They clearly represent the goal of the Avant-Garde program to support investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on the treatment of drug abuse."


'/>"/>

Contact: NIDA Press Team
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert

Related medicine news :

1. Transformative NIH grant will support development of tissue regeneration therapeutics
2. New strategy likely to speed drug development for rare cancers
3. Prenatal exposure to phthalates linked to decreased mental and motor development
4. Memory Development Incomplete Until Adulthood: Study
5. Researchers developing new test to measure risk for birth defects and neuro-developmental disorders
6. Sweet insight: Discovery could speed drug development
7. AMRI receives NIH contract award for development of pre-clinical drug candidates
8. NIH Blueprint empowers drug development for nervous system disorders
9. Penn researchers describe key molecule that keeps immune cell development on track
10. Sharing Bed With Toddler Wont Harm Development: Study
11. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March ... the coding audit process for all medical chart types with a comprehensive set ...
(Date:3/23/2017)... ... , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to ... the creation of published author, Desiree M Webb, a registered nurse, minister of music, ... happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To Atheist ... To Atheist Manifesto” is the creation of published author Richard Hostetter, a former ... years. He holds graduate degrees from Kent State University and the University of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... today announced the publication of “Profiling protein expression in circulating tumor cells using ... publication describes the use of the Vortex technology to capture CTCs ...
(Date:3/22/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had won the ‘Clinical Supply Chain Excellence’ category ... International Exhibition & Convention Centre, Singapore. The award was presented at the conference ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Inc. today announced the appointment of Martyn Coombs as ... of ImaginAb, said "At ImaginAb we have exciting science and technology. ... our business, particularly in commercializing and making step changes in the ... realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear medicine and ...
(Date:3/22/2017)... N.J. , March 22, 2017  CANTEL MEDICAL CORP. ... B. Hansen , President and CEO, will be presenting at ... at the Westin Grand Central Hotel in New ... April 5, 2017 at 3:00 p.m. ET. In addition, management ... A live audio webcast will be available ...
(Date:3/22/2017)... 22, 2017 Research and Markets has ... Inhibitors Market & Clinical Pipeline Insight 2022" drug pipelines ... ... Clinical Pipeline Insight 2022 report gives comprehensive insight on clinical ... immune check point inhibitors as main streamline drugs in the ...
Breaking Medicine Technology: